MHRA and the use of RWE

Why an OHDSI study-a-thon?

Katherine Donegan, Head of Epidemiology

23 January 2024
MHRA: Who are we?!

We are the regulator of medicines, medical devices and blood components for transfusion in the UK.

Our responsibilities include:
- ensure medicines and medical devices meet applicable standards of safety, quality and efficacy
- educate the public and healthcare professionals about the risks and benefits of medicines and medical devices and blood components, leading to safer and more effective use
- enable innovation and research and development that is beneficial to public health
- collaborate with partners in the UK and internationally to support our mission to enable the earliest access to safe medicines and medical devices and to protect public health

<table>
<thead>
<tr>
<th>Scientific Research and Innovation</th>
<th>Healthcare Quality and Access</th>
<th>Safety and Surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Innovation accelerator</td>
<td>• Enabling access to innovative medicines and devices</td>
<td>• Robust vigilance</td>
</tr>
<tr>
<td>• Clinical investigations and trials</td>
<td>• Population health</td>
<td>• Implementation of evidence-based risk mitigation</td>
</tr>
<tr>
<td>• Research and development</td>
<td></td>
<td>• Public health</td>
</tr>
</tbody>
</table>
Transforming vigilance: our ambitions

- Engaging and transparent
- Fully integrated into the healthcare system
- Prediction and risk minimization through pharmaco-genomics
- Latest tools, innovation and improved data

Proactively monitoring and acting on insights across the product full lifecycle

Better use of data to provide insight to inform decisions on medical products but also to improve the efficiency of our operational processes.
Other drivers for increasing access to RWE

• Promoting innovation
  - Real world evidence to support authorisation
  - Innovative Licencing and Access Pathway – early identification of RWE needs
  - Early access to medicines scheme – requirements for proactive vigilance

• Recognised data gaps and opportunities
  - Independent medicines and medical devices safety review
  - Life sciences vision
  - Opportunity to build around the Clinical Practice Research Datalink

• Evolving landscape
  - Improvements to data particularly for medical devices
  - Advancing analytical methodologies and pipelines
  - COVID-19 experience
  - Role of regulators promoting robust use of RWE
MHRA Study-a-thon: Fluoroquinolones & Rectopexy Mesh

Aims:

- Characterise use of fluoroquinolones in UK to monitor impact of RMMs
- Increase understanding on epidemiology of rectal prolapse & rectopexy (& associated outcomes).
- Increase understanding of utility of OMOP CDM
- Understand implications of CDM on robustness, timeliness, & availability of data
- Understand contribution to data gaps – particularly devices
Copyright information

© Crown copyright 2022
Produced by the Medicines and Healthcare products Regulatory Agency

You may re-use this information (excluding logos) with the permission from the Medicines and Healthcare products Regulatory Agency, under a Delegation of Authority. To view the guideline, visit https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information or email: copyright@mhra.gov.uk.

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

The names, images and logos identifying the Medicines and Healthcare products Regulatory Agency are proprietary marks. All the Agency’s logos are registered Trademarks and cannot be used without the Agency’s explicit permission.